Lilly obtains temporary restraining order to halt launch of generic Evista

Teva had indicated it was prepared to launch the generic version prior to the resolution of outstanding patent litigation currently being heard by the US District Court of Indiana.

Evista is a medicine indicated for the treatment and prevention of osteoporosis in postmenopausal women; and the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

Robert Armitage, senior vice president and general counsel of Lilly, said: “We appreciate the court issuing the temporary restraining order and look forward to completing the trial and vindicating our patent rights.

“We believe Teva’s challenges to Lilly’s Evista patent are without merit and we expect to prevail in this litigation. We have taken and will continue to take all appropriate actions needed to protect our intellectual property rights as they relate to Evista.”